|
1
|
Hu B, Guo H, Zhou P and Shi ZL:
Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol.
19:141–154. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Worldometer: COVID-19 Coronavirus
Pandemic. Available from: https://www.worldometers.info/coronavirus/#countries.
2023. Accessed December 3, 2023.
|
|
3
|
World Health Organization: WHO COVID-19
Dashboard. Dashboard. Available from: https://covid19.who.int. 2023. Accessed December 3,
2023.
|
|
4
|
World Health Organization: Egypt.
Available from: https://www.who.int/countries/egy. Accessed December
3, 2023.
|
|
5
|
World Health Organization: WHO COVID-19
Dashboard. COVID-19 Vaccination, Egypt data. Available from:
https://data.who.int/dashboards/covid19/vaccines?m49=818.
Accessed December 3, 2023.
|
|
6
|
Assaad R, Krafft C, Marouani MA, Kennedy
S, Cheung R and Wahby S: Egypt COVID-19 Country Case Study.
International Labour Organization/ILO/Economic Research Forum,
2022.
|
|
7
|
Barek MA, Aziz MA and Islam MS: Impact of
age, sex, comorbidities and clinical symptoms on the severity of
COVID-19 cases: A meta-analysis with 55 studies and 10014 cases.
Heliyon. 6(e05684)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tjendra Y, Al Mana AF, Espejo AP, Akgun Y,
Millan NC, Gomez-Fernandez C and Cray C: Predicting disease
severity and outcome in COVID-19 patients: A review of multiple
biomarkers. Arch Pathol Lab Med. 144:1465–1474. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Shafqat A, Shafqat S, Salameh SA, Kashir
J, Alkattan K and Yaqinuddin A: Mechanistic insights into the
immune pathophysiology of COVID-19; an in-depth review. Front
Immunol. 13(835104)2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y,
Jia Z, Guo L, Yang J, Wang C, Jiang S, et al: Heightened innate
immune responses in the respiratory tract of COVID-19 patients.
Cell Host Microbe. 27:883–890.e2. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ramasamy S and Subbian S: Critical
determinants of cytokine storm and type I interferon response in
COVID-19 pathogenesis. Clin Microbiol Rev. 34:00299–20.
2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mueller AL, McNamara MS and Sinclair DA:
Why does COVID-19 disproportionately affect older people? Aging
(Albany NY). 12:9959–9981. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Goswami GG, Mahapatro M, Ali A and Rahman
R: Do old age and comorbidity via non-communicable diseases matter
for COVID-19 mortality? A path analysis. Front Public Health.
9(736347)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Polack FP, Thomas SJ, Kitchin N, Absalon
J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED,
Zerbini C, et al: Safety and efficacy of the BNT162b2 mRNA Covid-19
vaccine. N Engl J Med. 383:2603–2615. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Baden LR, El Sahly HM, Essink B, Kotloff
K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB,
et al: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N
Engl J Med. 384:403–416. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Voysey M, Clemens SAC, Madhi SA, Weckx LY,
Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE,
et al: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)
against SARS-CoV-2: An interim analysis of four randomised
controlled trials in Brazil, South Africa, and the UK. Lancet.
397:99–111. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sadoff J, Gray G, Vandebosch A, Cárdenas
V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H,
Spiessens B, et al: Safety and efficacy of single-dose Ad26.COV2.S
vaccine against Covid-19. N Engl J Med. 384:2187–2201.
2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Moustafa RI, Faraag AH, El-Shenawy R, Agwa
MM and Elsayed H: Harnessing immunoinformatics for developing a
multiple-epitope peptide-based vaccination approach against
SARS-CoV-2 spike protein. Saudi J Biol Sci.
30(103661)2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Keech C, Albert G, Cho I, Robertson A,
Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, et al:
Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein
nanoparticle vaccine. N Engl J Med. 383:2320–2332. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
CDC: Underlying Conditions and the Higher
Risk for Severe COVID-19. Available from: https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html#:~:text=Based%20on%20data%20from%20the.
Accessed September 20, 2024.
|
|
21
|
Ko JY, Danielson ML, Town M, Derado G,
Greenlund KJ, Kirley PD, Alden NB, Yousey-Hindes K, Anderson EJ,
Ryan PA, et al: Risk factors for coronavirus disease 2019
(COVID-19)-associated hospitalization: COVID-19-associated
hospitalization surveillance network and behavioral risk factor
surveillance system. Clin Infect Dis. 72:e695–e703. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Siegel M, Critchfield-Jain I, Boykin M,
Owens A, Nunn T and Muratore R: Actual racial/ethnic disparities in
COVID-19 mortality for the non-Hispanic Black compared to
non-Hispanic White population in 353 US counties and their
association with structural racism. J Racial Ethn Health
Disparities. 9:1697–1725. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Centers for Disease Control and
Prevention. Provisional COVID-19 Deaths: Distribution of Deaths by
Race and Hispanic Origin. Available from: https://data.cdc.gov/NCHS/Provisional-COVID-19-Deaths-Distribution-of-Deaths/pj7m-y5uh/about_data.
Accessed February 9, 2023.
|
|
24
|
Gao LJ, He ZM, Li YY, Yang RR, Yan M,
Shang X and Cao JM: Role of OAS gene family in COVID-19 induced
heart failure. J Transl Med. 21(212)2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gajate-Arenas M, Fricke-Galindo I,
García-Pérez O, Domínguez-de-Barros A, Pérez-Rubio G, Dorta-Guerra
R, Buendía-Roldán I, Chávez-Galán L, Lorenzo-Morales J,
Falfán-Valencia R and Córdoba-Lanús E: The immune response of OAS1,
IRF9, and IFI6 genes in the pathogenesis of COVID-19. Int J Mol
Sci. 25(4632)2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Rebouillat D and Hovanessian AG: The human
2',5'-oligoadenylate synthetase family: Interferon-induced proteins
with unique enzymatic properties. J Interferon Cytokine Res.
19:295–308. 1999.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Bader El Din NG, Anany MA, Dawood RM,
Ibrahim MK, El-Shenawy R, El Abd YS and El Awady MK: Impact of OAS1
exon 7 rs10774671 genetic variation on liver fibrosis progression
in Egyptian HCV genotype 4 patients. Viral Immunol. 28:509–516.
2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Schwartz SL and Conn GL: RNA regulation of
the antiviral protein 2'-5'-oligoadenylate synthetase. Wiley
Interdiscip Rev RNA. 10(e1534)2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kjær KH, Pahus J, Hansen MF, Poulsen JB,
Christensen EI, Justesen J and Martensen PM: Mitochondrial
localization of the OAS1 p46 isoform associated with a common
single nucleotide polymorphism. BMC Cell Biol.
15(33)2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Huffman JE, Butler-Laporte G, Khan A,
Pairo-Castineira E, Drivas TG, Peloso GM and Nakanishi T: COVID-19
Host Genetics Initiative. Ganna A, Verma A, et al: Multi-ancestry
fine mapping implicates OAS1 splicing in risk of severe COVID-19.
Nat Genet. 54:125–127. 2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhou S, Butler-Laporte G, Nakanishi T,
Morrison DR, Afilalo J, Afilalo M, Laurent L, Pietzner M, Kerrison
N, Zhao K, et al: A Neanderthal OAS1 isoform protects individuals
of European ancestry against COVID-19 susceptibility and severity.
Nat Med. 27:659–667. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
El Awady MK, Anany MA, Esmat G, Zayed N,
Tabll AA, Helmy A, El Zayady AR, Abdalla MS, Sharada HM, El Raziky
M, et al: Single nucleotide polymorphism at exon 7 splice acceptor
site of OAS1 gene determines response of hepatitis C virus patients
to interferon therapy. J Gastroenterol Hepatol. 26:843–850.
2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ghosh A, Sarkar SN, Rowe TM and Sen GC: A
specific isozyme of 2'-5'oligoadenylate synthetase is a dual
function proapoptotic protein of the Bcl-2 family. J Biol Chem.
276:25447–25455. 2001.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bonnevie-Nielsen V, Field LL, Lu S, Zheng
DJ, Li M, Martensen PM, Nielsen TB, Beck-Nielsen H, Lau YL and
Pociot F: Variation in antiviral 2',5'-oligoadenylate synthetase
(2'5'AS) enzyme activity is controlled by a single-nucleotide
polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum
Genet. 76:623–633. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
Sams AJ, Dumaine A, Nédélec Y, Yotova V,
Alfieri C, Tanner JE, Messer PW and Barreiro LB: Adaptively
introgressed Neandertal haplotype at the OAS locus functionally
impacts innate immune responses in humans. Genome Biol.
17(246)2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Yousfi FZE, Haroun AE, Nebhani C,
Belayachi J, Askander O, Fahime EE, Fares H, Ennibi K, Abouqal R,
Razine R and Bouhouche A: Prevalence of the protective OAS1
rs10774671-G allele against severe COVID-19 in Moroccans:
Implications for a North African Neanderthal connection. Arch
Virol. 169(109)2024.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wickenhagen A, Sugrue E, Lytras S, Kuchi
S, Noerenberg M, Turnbull ML, Loney C, Herder V, Allan J, Jarmson
I, et al: A prenylated dsRNA sensor protects against severe
COVID-19. Science. 374(eabj3624)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Banday AR, Stanifer ML, Florez-Vargas O,
Onabajo OO, Papenberg BW, Zahoor MA, Mirabello L, Ring TJ, Lee CH,
Albert PS, et al: Genetic regulation of OAS1 nonsense-mediated
decay underlies association with COVID-19 hospitalization in
patients of European and African ancestries. Nat Genet.
54:1103–1116. 2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kotb E, Ouerfelli N, Zrelli N, Briki K,
Ahmed AA, Medhat MA, Elsayed H and El-Kassas M: Empirical modeling
for reported cases and deaths of COVID-19 in Egypt during the
accelerated spread and prediction of the delayed phase. Bull
Pharmaceutical Sci Assiut. 45:775–788. 2022.
|
|
40
|
El Kassas M, Asem N, Abdelazeem A, Madkour
A, Sayed H, Tawheed A, Al Shafie A, Gamal M, Elsayed H, Badr M, et
al: Clinical features and laboratory characteristics of patients
hospitalized with COVID-19: Single centre report from Egypt. J
Infect Dev Ctries. 14:1352–1360. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Von Elm E, Altman DG, Egger M, Pocock SJ,
Gøtzsche PC and Vandenbroucke JP: STROBE Initiative. The
strengthening the reporting of observational studies in
epidemiology (STROBE) statement: Guidelines for reporting
observational studies. Int J Surg. 12:1495–1499. 2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hussain M, Jabeen N, Raza F, Shabbir S,
Baig AA, Amanullah A and Aziz B: Structural variations in human
ACE2 may influence its binding with SARS-CoV-2 spike protein. J Med
Virol. 92:1580–1586. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Torre-Fuentes L, Matías-Guiu J,
Hernández-Lorenzo L, Montero-Escribano P, Pytel V, Porta-Etessam J,
Gómez-Pinedo U and Matías-Guiu JA: ACE2, TMPRSS2, and Furin
variants and SARS-CoV-2 infection in Madrid, Spain. J Med Virol.
93:863–869. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Gómez J, Albaiceta GM, Cuesta-Llavona E,
García-Clemente M, López-Larrea C, Amado-Rodríguez L, López-Alonso
I, Melón S, Alvarez-Argüelles ME, Gil-Peña H, et al: The
Interferon-induced transmembrane protein 3 gene (IFITM3) rs12252 C
variant is associated with COVID-19. Cytokine.
137(155354)2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Lim JK, Lisco A, McDermott DH, Huynh L,
Ward JM, Johnson B, Johnson H, Pape J, Foster GA, Krysztof D, et
al: Genetic variation in OAS1 is a risk factor for initial
infection with West Nile virus in man. PLoS Pathog.
5(e1000321)2009.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Noguchi S, Hamano E, Matsushita I,
Hijikata M, Ito H, Nagase T and Keicho N: Differential effects of a
common splice site polymorphism on the generation of OAS1 variants
in human bronchial epithelial cells. Hum Immunol. 74:395–401.
2013.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Tessier M-C, Qu H-Q, Fréchette R, Bacot F,
Grabs R, Taback SP, Lawson ML, Kirsch SE, Hudson TJ and
Polychronakos C: Type 1 diabetes and the OAS gene cluster:
Association with splicing polymorphism or haplotype? J Med Genet.
43:129–132. 2005.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Cagliani R, Fumagalli M, Guerini FR, Riva
S, Galimberti D, Comi GP, Agliardi C, Scarpini E, Pozzoli U, Forni
D, et al: Identification of a new susceptibility variant for
multiple sclerosis in OAS1 by population genetics analysis. Hum
Genet. 131:87–97. 2012.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Wu S, Wang Y, Chen G, Zhang M, Wang M and
He JQ: 2'-5'-Oligoadenylate synthetase 1 polymorphisms are
associated with tuberculosis: A case-control study. BMC Pulm Med.
18(180)2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Zeberg H and Pääbo S: A genomic region
associated with protection against severe COVID-19 is inherited
from Neandertals. Proc Natl Acad Sci USA.
118(e2026309118)2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Pasrija R and Naime M: The deregulated
immune reaction and cytokines release storm (CRS) in COVID-19
disease. Int Immunopharmacol. 90(107225)2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Gao YM, Xu G, Wang B and Liu BC: Cytokine
storm syndrome in coronavirus disease 2019: A narrative review. J
Inter Med. 289:147–161. 2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
D'Antonio M, Nguyen JP, Arthur TD and
Matsui H: COVID-19 Host Genetics Initiative. D'Antonio-Chronowska A
and Frazer KA: SARS-CoV-2 susceptibility and COVID-19 disease
severity are associated with genetic variants affecting gene
expression in a variety of tissues. Cell Rep.
37(110020)2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Kozak K, Pavlyshyn H, Kamyshnyi O,
Shevchuk O, Korda M and Vari SG: The Relationship between COVID-19
Severity in Children and Immunoregulatory Gene Polymorphism.
Viruses. 15(2093)2023.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Simon-Loriere E, Lin RJ, Kalayanarooj SM,
Chuansumrit A, Casademont I, Lin SY, Yu HP, Lert-Itthiporn W,
Chaiyaratana W, Tangthawornchaikul N, et al: High anti-dengue virus
activity of the OAS gene family is associated with increased
severity of dengue. J Infect Dis. 212:2011–2020. 2015.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Liu X, Xing H, Gao W, Yu D, Zhao Y, Shi X,
Zhang K, Li P, Yu J, Xu W, et al: A functional variant in the OAS1
gene is associated with Sjögren's syndrome complicated with HBV
infection. Sci Rep. 7(17571)2017.PubMed/NCBI View Article : Google Scholar
|
